Founded in 2017, 3T Biosciences is an immunotherapy company based in Menlo Park, California. The company's core mission is to develop next-generation, transformative TCR (T-cell receptor) therapies aimed at treating solid tumors and other immune-mediated diseases. By focusing on innovative immunotherapy solutions, 3T Biosciences seeks to revolutionize cancer treatment and improve outcomes for a broad range of patient populations.
Notable affiliated individuals and investors include leading experts in oncology and immunotherapy, although specific names are not provided. Key achievements for 3T Biosciences include advancing their TCR therapeutic programs through significant research milestones and clinical trials. The company's overall impact lies in its potential to offer groundbreaking treatments that could significantly alter the landscape of cancer therapy and other immune-related conditions.
